Grain Alliance November 11th | Cornerstone Pharmaceuticals-B(02616.HK) announced that the company unveiled the preclinical data of the heavyweight product CS2009 at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). CS2009 is a trispecific antibody targeting PD-1, CTLA-4, and VEGFA.

Key Highlights

• CS2009 is a trispecific antibody targeting PD-1, CTLA-4, and VEGFA.

• Preclinical data shows that CS2009 exhibits significantly better anti-tumor activity than potential competitors.

• CS2009 is expected to cover a wide range of tumors and become the next generation of tumor immune framework products that are either first in class or best in class.

• Cornerstone Pharmaceuticals plans to submit an Investigational New Drug (IND) application for CS2009 by the end of 2024 or early 2025, and initiate first human studies in early 2025.

Dr. Yang Jianxin, CEO, Chief R&D Officer, and Executive Director of Cornerstone Pharmaceuticals, said: "We are pleased to announce the latest preclinical data of CS2009 at the SITC Annual Meeting, marking its debut on the international academic stage. As a cornerstone product in the pipeline 2.0, CS2009 is a potential next-generation tumor immune framework product that is either first in class or best in class, with the prospect of replacing existing PD-(L)1 therapy. The outstanding preclinical data of CS2009 further enhances our confidence in the subsequent clinical development. We look forward to seeing CS2009 benefit patients, especially those with non-small cell lung cancer, ovarian cancer, renal cell carcinoma, cervical cancer, hepatocellular carcinoma, and gastric cancer, particularly the group with low PD-L1 expression or PD-L1 negativity who respond poorly to PD-(L)1 therapy."